Alexander's(ALX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALX Alexander's

Post-Mkt 01-16 16:00:27 EST

241.48

+6.41

+2.73%

盘后240.83

-0.65-0.27%

16:00 EST

High241.78	Low234.55	Vol132.02K
Open234.55	D1 Closing235.07	Amplitude3.08%
Mkt Cap1.23B	Tradable Cap513.31M	Total Shares5.11M
T/O31.41M	T/O Rate6.21%	Tradable Shares2.13M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALX","market":"US","secType":"STK","nameCN":"Alexander's","latestPrice":241.48,"timestamp":1768597199947,"preClose":235.07,"halted":0,"volume":132018,"hourTrading":{"tag":"盘后","latestPrice":240.83,"preClose":241.48,"latestTime":"16:00 EST","volume":2,"amount":481.66,"timestamp":1768597211934},"delay":0,"floatShares":2125671,"shares":5107290,"eps":7.139782,"marketStatus":"Post-Mkt","change":6.41,"latestTime":"01-16 16:00:27 EST","open":234.55,"high":241.78,"low":234.55,"amount":31410509.387280002,"amplitude":0.030757,"askPrice":242,"askSize":1,"bidPrice":228,"bidSize":1,"shortable":3,"etf":0,"ttmEps":7.139782,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1768611600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":-7416000000,"exchange":"NYSE","adjPreClose":235.07,"dividendRate":0.074567,"postHourTrading":{"tag":"盘后","latestPrice":240.83,"preClose":241.48,"latestTime":"16:00 EST","volume":2,"amount":481.66,"timestamp":1768597211934},"volumeRatio":1.655553},"requestUrl":"/m/hq/s/ALX/wiki","defaultTab":"wiki","newsList":[{"id":"2601765367","title":"ALX Oncology first patient dosed in Phase 2 ASPEN-09-Breast trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2601765367","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601765367?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:55","pubTimestamp":1767880550,"startTime":"0","endTime":"0","summary":"ALX Oncology (ALXO) announced that the first patient has been dosed in the Company’s Phase 2 ASPEN-09-Breast trial evaluating its investigational C...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alx-oncology-first-patient-dosed-in-phase-2-aspen-09-breast-trial-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alx-oncology-first-patient-dosed-in-phase-2-aspen-09-breast-trial-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4231","BK4139","BK4080","ALXO","ALX"],"gpt_icon":0},{"id":"2601236783","title":"ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004","url":"https://stock-news.laohu8.com/highlight/detail?id=2601236783","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601236783?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:30","pubTimestamp":1767879000,"startTime":"0","endTime":"0","summary":"- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy in HER2-positive metastatic breast cancer; interim a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/08/3215379/0/en/ALX-Oncology-Advances-Separate-Clinical-Trials-Evaluating-Investigational-CD47-Inhibitor-Evorpacept-and-Novel-EGFR-Targeted-Antibody-Drug-Conjugate-ALX2004.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","LU0456854461.SGD","BK4080","OS","BK4211","BK4097","PFS","LU0266512127.USD","ALX","CRC","ORR","BK4231","BK4213","ADC"],"gpt_icon":0},{"id":"2595728733","title":"Alexander’s Completes Restructuring of Retail Loan at 731 Lexington Avenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2595728733","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595728733?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:44","pubTimestamp":1767015840,"startTime":"0","endTime":"0","summary":"PARAMUS, N.J., Dec.  29, 2025  (GLOBE NEWSWIRE) -- Alexander’s, Inc. (NYSE: ALX) today announced that it has restructured the $300 million mortgage loan on the retail condominium of 731 Lexington Aven","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/29/3210929/0/en/Alexander-s-Completes-Restructuring-of-Retail-Loan-at-731-Lexington-Avenue.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","ALX","BK4231"],"gpt_icon":0},{"id":"2590532821","title":"Alexander’s (ALX) Valuation After Rego Park II Refinancing and New $175 Million Interest-Only Loan","url":"https://stock-news.laohu8.com/highlight/detail?id=2590532821","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590532821?lang=en_us&edition=fundamental","pubTime":"2025-12-11 02:16","pubTimestamp":1765390618,"startTime":"0","endTime":"0","summary":"Alexander's (ALX) just reshaped its balance sheet by refinancing the Rego Park II shopping center with a $175 million interest only loan maturing in 2030, while trimming its prior debt load.\nSee our latest analysis for Alexander's.\nAgainst that backdrop, Alexander's 10.1% year to date share price return and 9.7% one year total shareholder return suggest steady but not explosive momentum, with the recent refinancing potentially easing some balance sheet risk concerns.\nIf you are weighing how...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551736-choice2-main-header/1585186602415","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551736-choice2-main-header/1585186602415"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/real-estate/nyse-alx/alexanders/news/alexanders-alx-valuation-after-rego-park-ii-refinancing-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/real-estate/nyse-alx/alexanders/news/alexanders-alx-valuation-after-rego-park-ii-refinancing-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4080","BK7090","DCF","BK4231","ALX","ALX.AU"],"gpt_icon":0},{"id":"2590341096","title":"Alexander’s Completes $175 Million Refinancing of Rego Park Ii","url":"https://stock-news.laohu8.com/highlight/detail?id=2590341096","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590341096?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:59","pubTimestamp":1765288741,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUAB9MGKJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4231","BK4080","ALX"],"gpt_icon":0},{"id":"2590349058","title":"Alexander's Inc. Secures $175 Million Refinancing for Rego Park II Shopping Center","url":"https://stock-news.laohu8.com/highlight/detail?id=2590349058","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590349058?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:27","pubTimestamp":1765286872,"startTime":"0","endTime":"0","summary":"Alexander's Inc. has completed a $175 million refinancing of its 615,000 square foot Rego Park II shopping center in Queens, New York. The new interest-only loan carries a rate of SOFR plus 2.00%, currently 5.82%, and matures in December 2030. As part of the refinancing, Alexander's paid down $23.5 million from the previous $198.5 million loan, which had an interest rate of SOFR plus 1.45% and was set to mature in December 2025. Alexander's Inc. is a real estate investment trust with five properties in New York City.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alexander's Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDLbbvKyH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","BK4231","ALX"],"gpt_icon":0},{"id":"2589877324","title":"ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2589877324","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589877324?lang=en_us&edition=fundamental","pubTime":"2025-12-07 21:00","pubTimestamp":1765112400,"startTime":"0","endTime":"0","summary":"- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an appr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/07/3201128/0/en/ALX-Oncology-Announces-Positive-Results-from-Ongoing-Investigator-Sponsored-Phase-2-Trial-Evaluating-Evorpacept-in-Combination-with-Standard-of-Care-Treatment-in-Patients-with-Indo.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4213","BK4109","LU2463526074.USD","BK4080","ORR","BK4124","ASH","CR","SMP","PFS","ALX","PR","BK4231","BK4161","BK4097","OS","BK4211"],"gpt_icon":0},{"id":"2588725758","title":"Henderson Land Development Files Directors List to HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2588725758","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588725758?lang=en_us&edition=fundamental","pubTime":"2025-12-01 18:04","pubTimestamp":1764583491,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Henderson Land Development Company Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL39Kxn9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4194","ALX","BK4231","BK1559","BK4588","BK1240","BK1601","BK4585","00012","BK4223","VNO","BK4080"],"gpt_icon":0},{"id":"2587791380","title":"PT International Development Corporation Files Directors List to HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2587791380","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587791380?lang=en_us&edition=fundamental","pubTime":"2025-11-30 18:10","pubTimestamp":1764497433,"startTime":"0","endTime":"0","summary":"PT International Development Corporation Limited has announced an updated list of directors and their respective roles and committee memberships, as filed with the Hong Kong Exchanges and Clearing Limited. The Board comprises Mr. Ching Man Chun, Louis  and Mr. Wong Kung Ho, Alexander as Executive Directors; Ms. Wong Man Ming, Melinda as Non-executive Director; and Mr. Yam Kwong Chun, Mr. Wong Yee Shuen, Wilson, and Mr. Lam Yik Tung as Independent Non-executive Directors. In terms of committee memberships, Mr. Wong Yee Shuen, Wilson serves as Chairman of the Audit Committee, and Mr. Lam Yik Tung chairs the Remuneration Committee. Mr. Yam Kwong Chun is Chairman of the Nomination Committee, while Mr. Ching Man Chun, Louis chairs the Corporate Governance Committee. Other committee members include Ms. Wong Man Ming, Melinda , with Mr. Yam Kwong Chun, Mr. Wong Yee Shuen, Wilson, and Mr. Lam Yik Tung also serving as members across the various committees.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251130:nNDL8HqWJl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4194","BK4588","BK4231","ALX","00372","VNO","BK4223","BK1124","BK4080","BK4585"],"gpt_icon":0},{"id":"2584195102","title":"ALX Oncology to Present at Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2584195102","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584195102?lang=en_us&edition=fundamental","pubTime":"2025-11-19 00:00","pubTimestamp":1763481600,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Nov.  18, 2025  (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (\"ALX Oncology\" or the \"Company\") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/18/3190290/0/en/ALX-Oncology-to-Present-at-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","LABU","BK4585","BK4588","ALX","XLV","XBI","BK4231","BK4581"],"gpt_icon":0},{"id":"2584617074","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584617074","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584617074?lang=en_us&edition=fundamental","pubTime":"2025-11-17 15:30","pubTimestamp":1763364624,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Fate Therapeutics (FATE – Research Report), ALX On...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-fate-therapeutics-fate-alx-oncology-holdings-alxo-and-60-degrees-pharmaceuticals-inc-sxtp-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-fate-therapeutics-fate-alx-oncology-holdings-alxo-and-60-degrees-pharmaceuticals-inc-sxtp-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LU0029874061.USD","BK4139","BK4137","SXTP","BK4581","ALXO","FATE","HCSG","XLV","BK4080","LABU","BK4231","BK4585","ALX","BK4588","XBI","LU0128526141.USD"],"gpt_icon":0},{"id":"2583184595","title":"ALX Oncology Holdings (ALXO) Gets a Buy from Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2583184595","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583184595?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:57","pubTimestamp":1763042257,"startTime":"0","endTime":"0","summary":"Jefferies analyst initiated coverage with a Buy rating on ALX Oncology Holdings today and set a price target of $4.00. In addition to Jefferies, AL...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/alx-oncology-holdings-alxo-gets-a-buy-from-jefferies-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/alx-oncology-holdings-alxo-gets-a-buy-from-jefferies-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4080","ALX","BK4139","BK4231","ALXO"],"gpt_icon":0},{"id":"2583589413","title":"Assessing Atlas Arteria (ASX:ALX) Valuation Following Executive Restructuring and Strategic Refocus","url":"https://stock-news.laohu8.com/highlight/detail?id=2583589413","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583589413?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:24","pubTimestamp":1762982669,"startTime":"0","endTime":"0","summary":"Atlas Arteria (ASX:ALX) has announced a major overhaul of its executive team, reducing the number of leaders from six to four and broadening each role’s responsibilities to better support the company’s strategic priorities.\nSee our latest analysis for Atlas Arteria.\nRecent executive changes signal Atlas Arteria’s renewed push for efficiency, and the market seems to have taken notice. The company has seen a 7.1% 30-day share price return after a period of softer momentum earlier this year...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/3252000-choice2-main-header/1585187464700","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3252000-choice2-main-header/1585187464700"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/transportation/asx-alx/atlas-arteria-shares/news/assessing-atlas-arteria-asxalx-valuation-following-executive","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/transportation/asx-alx/atlas-arteria-shares/news/assessing-atlas-arteria-asxalx-valuation-following-executive","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4231","BK4080","ALX.AU","ALX","BK7090","DCF"],"gpt_icon":0},{"id":"2582737583","title":"Ovid Therapeutics reports Q3 revenue of $132,000 and R&D expenses of $5.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582737583","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582737583?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:03","pubTimestamp":1762949005,"startTime":"0","endTime":"0","summary":"Ovid Therapeutics Inc. reported cash, cash equivalents and marketable securities of $25.6 million as of September 30, 2025. This was supplemented by an $81 million private placement in October 2025, with up to an additional $94 million possible from warrants. Revenue from royalty agreements for the third quarter was $0.1 million, compared to $0.2 million in the same period in 2024. Research and development expenses decreased to $5.9 million from $7.9 million, while general and administrative expenses increased to $6.8 million from $5.5 million. Total operating expenses were $12.7 million, down from $13.4 million a year earlier. The net loss for the quarter was $12.2 million, or $0.17 per share, compared to a net loss of $14.0 million, or $0.20 per share, in 2024. Key business developments include the appointment of Meg Alexander as CEO effective January 1, 2026, and advancement of OV329, a next-generation GABA-aminotransferase inhibitor, which showed strong Phase 1 results and will pro","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL10fNfq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4194","BK4231","BK4139","BK4223","BK4080","BK4588","VNO","BK4585","ALX","OVID"],"gpt_icon":0},{"id":"2582037315","title":"Ovid Therapeutics Names Meg Alexander as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2582037315","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582037315?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948845,"startTime":"0","endTime":"0","summary":"Ovid Therapeutics Inc. announced that Meg Alexander will become Chief Executive Officer and join the Board of Directors effective January 1, 2026. Dr. Jeremy M. Levin, the current Chairman and CEO, will transition to the role of Executive Chairman of the Board.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 12, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL3WD5sS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4223","OVID","VNO","LU2210149790.SGD","BK4139","LU2095319765.USD","IE00BGHQF748.EUR","BK4194","BK4588","NDAQ","BK4080","ALX","BK4585","LU0314104364.USD","BK4112","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4231","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2582251330","title":"Is Analyst Optimism Outweighing Earnings Weakness in Shaping Alexander's (ALX) Investment Case?","url":"https://stock-news.laohu8.com/highlight/detail?id=2582251330","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582251330?lang=en_us&edition=fundamental","pubTime":"2025-11-11 14:19","pubTimestamp":1762841978,"startTime":"0","endTime":"0","summary":"Alexander's, Inc. recently reported third-quarter earnings, noting sales of US$53.42 million and net income of US$5.97 million, both lower than the prior year's results, and reaffirmed a quarterly dividend of US$4.50 per share payable later this month.\nDespite these year-over-year declines in sales and earnings, strong analyst sentiment has led to an upward revision in full-year earnings estimates and elevated the company to a top ranking by Zacks.\nWe'll examine how the improved analyst...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551736-choice2-main-header/1585186602415","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551736-choice2-main-header/1585186602415"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/real-estate/nyse-alx/alexanders/news/is-analyst-optimism-outweighing-earnings-weakness-in-shaping","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/real-estate/nyse-alx/alexanders/news/is-analyst-optimism-outweighing-earnings-weakness-in-shaping","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ALX.AU","ALX"],"gpt_icon":0},{"id":"2582878469","title":"OpenAI considers consumer health tools in push beyond core AI offerings, Business Insider reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2582878469","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582878469?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:52","pubTimestamp":1762775551,"startTime":"0","endTime":"0","summary":"Nov 10  - OpenAI is weighing building consumer health products, including a generative AI-powered personal health assistant, as the ChatGPT maker aims to move beyond its core offerings, Business Insider reported on Monday, citing sources close to the company.OpenAI did not immediately respond to a Reuters request for comment.Tech giants such as Google, Amazon and Microsoft have long tried to give consumers control over their medical data, often with limited success.Google GOOGL.O shut its health record service in 2011 due to low traction, while Amazon AMZN.O wound down its Halo fitness tracker business in 2023. Microsoft's MSFT.O HealthVault platform also failed to attract widespread adoption.OpenAI's healthcare push follows strategic hires, including Nate Gross, cofounder of physician network Doximity DOCS.N, as head of healthcare strategy in June, and former Instagram executive Ashley Alexander as vice president of health products in August.At the HLTH conference in October, Gross sa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL4N3WM0SR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0070217475.USD","VNO","LU0061475181.USD","LU0661504455.SGD","LU0312595415.SGD","LU2750360641.GBP","LU0889566641.SGD","LU1551013342.USD","USAW.SI","LU0162691827.USD","LU0158827781.USD","LU0323239441.USD","LU2471134523.USD","LU0708995401.HKD","LU2083900584.USD","SG9999014559.SGD","IE0009G5SDU7.USD","LU1066051498.USD","LU0345770993.USD","LU1181866309.USD","ALX","LU1989772923.USD","LU2462157665.USD","LU1989764748.USD","LU2471134879.HKD","DOCS","IE000YTNTUN2.SGD","LU1340139317.AUD","LU1839511570.USD","LU2471134796.USD","LU2360106780.USD","IE000ITXATA3.USD","LU2237957811.SGD","LU1989772840.SGD","LU1989764664.SGD","LU2750360997.AUD","LU0095938881.EUR","LU0079474960.USD","BK4507","LU0057025933.USD","LU0689626769.HKD","LU2237957902.USD","LU1935042488.USD","LU1496350171.SGD","LU2360108059.USD","LU0106261372.USD","LU0472753341.HKD"],"gpt_icon":1},{"id":"2582848337","title":"Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), ALX Oncology Holdings (ALXO) and Cencora (COR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582848337","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582848337?lang=en_us&edition=fundamental","pubTime":"2025-11-10 10:30","pubTimestamp":1762741830,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Veeva Systems (VEEV – Research Report), ALX Oncology Holdings (AL...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-veeva-systems-veev-alx-oncology-holdings-alxo-and-cencora-cor-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-veeva-systems-veev-alx-oncology-holdings-alxo-and-cencora-cor-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0266013472.USD","LU1989764748.USD","LU1084165304.USD","LU0128526141.USD","VEEV","ALXO","BK4504","LU0029874061.USD","LU2324357040.USD","SGXZ23171101.USD","BK4581","BK4585","LU0289739699.SGD","BK4529","LU2237957902.USD","BK4084","BK4167","LU0058720904.USD","BK4528","LABU","XBI","LU0170899867.USD","LU1430594728.SGD","BK4231","BK4137","BK4139","XLV","BK4080","ALX","BK4175","COR","LU1261432733.SGD","BK4613","HCSG","LU1814569148.SGD","BK4534","LU2237957811.SGD","BK4588","LU1585245621.USD","LU1119994496.HKD","SG9999004303.SGD","LU1989764664.SGD"],"gpt_icon":0},{"id":"2581839848","title":"ALX Oncology Holdings Q3 Adj. EPS $(0.36) Beats $(0.37) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581839848","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581839848?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:17","pubTimestamp":1762521436,"startTime":"0","endTime":"0","summary":"ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.37) by 1.91 percent. This is a 20 percent increase over losses of $(0.45) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48717173/alx-oncology-holdings-q3-adj-eps-0-36-beats-0-37-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALXO","ALX"],"gpt_icon":0},{"id":"2581886688","title":"ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2581886688","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581886688?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:15","pubTimestamp":1762521300,"startTime":"0","endTime":"0","summary":"ASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy measures in HER2+ gastric cancer patients with high CD47 expression Phase 2 ASPEN-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/07/3183623/0/en/ALX-Oncology-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","BK4097","IE00BD4GTV84.USD","BK4144","ALX","BK4566","IE00BMG7P819.SGD","IE00BMG7P694.USD","SITC","TRP","HR","BK4231","IE00BMG7P587.USD","BK4080","IE00BD4GTW91.USD","BK4195","IE00BMG7P926.USD","OS","BK4225","PFS","ORR","BK4211","IE00BD4GTT62.SGD","BK4203","IE00BMG7P702.HKD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alx-inc.com","stockEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":0.0843},{"period":"3month","weight":-0.0034},{"period":"6month","weight":-0.0305},{"period":"1year","weight":0.2291},{"period":"ytd","weight":0.0786}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0419},{"period":"6month","weight":0.103},{"period":"1year","weight":0.1678},{"period":"ytd","weight":0.0151}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alexander's, Inc. (NYSE: ALX) is a real estate investment trust (REIT), incorporated in Delaware, engaged in leasing, managing, developing and redeveloping its properties. All references to we, us, our, Company and Alexander's refer to Alexander's, Inc. and its consolidated subsidiaries. We are managed by, and our properties are leased and developed by, Vornado Realty Trust (Vornado) (NYSE: VNO). We have five properties in New York City.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.00964},{"month":2,"riseRate":0.466667,"avgChangeRate":0.004662},{"month":3,"riseRate":0.511111,"avgChangeRate":0.016839},{"month":4,"riseRate":0.434783,"avgChangeRate":0.00716},{"month":5,"riseRate":0.521739,"avgChangeRate":0.024688},{"month":6,"riseRate":0.5,"avgChangeRate":0.00582},{"month":7,"riseRate":0.586957,"avgChangeRate":0.014946},{"month":8,"riseRate":0.478261,"avgChangeRate":0.005583},{"month":9,"riseRate":0.5,"avgChangeRate":0.023298},{"month":10,"riseRate":0.521739,"avgChangeRate":0.013397},{"month":11,"riseRate":0.456522,"avgChangeRate":-0.006173},{"month":12,"riseRate":0.521739,"avgChangeRate":0.017167}],"exchange":"NYSE","name":"Alexander's","nameEN":"Alexander's"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alexander's(ALX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alexander's(ALX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alexander's,ALX,Alexander's股票,Alexander's股票老虎,Alexander's股票老虎国际,Alexander's行情,Alexander's股票行情,Alexander's股价,Alexander's股市,Alexander's股票价格,Alexander's股票交易,Alexander's股票购买,Alexander's股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alexander's(ALX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alexander's(ALX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}